Amphastar Pharmaceuticals (AMPH) Cash from Investing Activities (2013 - 2026)

Amphastar Pharmaceuticals' Cash from Investing Activities history runs 14 years deep, the most recent figure standing at -$16.7 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 259.65% year-over-year to -$16.7 million in Q1 2026; TTM through Mar 2026 was -$97.5 million, a 24.78% increase from a year earlier, with the FY2025 full-year figure at -$70.3 million, up 43.7% from the prior year.
• Cash from Investing Activities advanced to -$16.7 million in Q1 2026 per AMPH's latest filing, from -$60.6 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $15.2 million in Q1 2024 and bottomed at -$508.6 million in Q2 2023.
• The 5-year median for Cash from Investing Activities is -$16.7 million (2026), against an average of -$52.6 million.
• Across the five-year window, Cash from Investing Activities tumbled 44899.56% in 2023 and soared 340.6% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at -$229000.0 in 2022, then tumbled by 44899.56% to -$103.0 million in 2023, then surged by 65.38% to -$35.7 million in 2024, then plunged by 69.77% to -$60.6 million in 2025, then jumped by 72.37% to -$16.7 million in 2026.
• Per Business Quant, the three latest AMPH Cash from Investing Activities figures stand at -$16.7 million (Q1 2026), -$60.6 million (Q4 2025), and -$19.6 million (Q3 2025).